当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.

Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemia.

Abstract：

:The use of etoposide (VP-16) for stem cell mobilization has been reported as a significant risk factor for the development of therapy-related myelodysplasia/therapy-related AML (tMDS/tAML) after transplantation. We compared the safety and effectiveness of VP-16+G-CSF (VP+G) to G-CSF alone for PBPC mobilization in patients with non-Hodgkin's lymphoma and Hodgkin's lymphoma who underwent autologous transplantation at the Cleveland Clinic and Ohio State University. In the VP+G group, median total CD34+ cells collected were 9.34 × 10(6) per kg (range 0.97-180.89), with 42% of all patients having adequate (2 × 10(6) cells per kg) CD 34+ collection after 2 days of apheresis compared with a median in the G-CSF group of 3.83 × 10(6) per kg (range, 0.72-50.38), with only 16% patients having adequate collection after 2 days (P<0.001). tMDS/tAML occurred in 15 patients (2.3%) in the VP+G and in 12 patients (3.8%) receiving G-CSF alone. (P=0.62). Increased number of days of apheresis was associated with the risk of tMDS/tAML (hazard ratio (HR) 1.19, 95% confidence interval (CI) 1.08-1.30, P<0.001). Priming regimen was not a significant variable for relapse-free survival or OS. The addition of etoposide significantly improves the effectiveness of mobilization at the cost of an increased incidence of neutropenic fever though with no mortalities. There is no evidence of increased incidence of tMDS/tAML in patients receiving VP+G compared with those mobilized with G-CSF alone.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Mahindra A,Bolwell BJ,Rybicki L,Elder P,Kalaycio M,Dean R,Avalos B,Sobecks R,Tench S,Andresen S,Pohlman B,Sweetenham J,Devine S,Copelan E

doi

10.1038/bmt.2011.73

subject

Has Abstract

pub_date

2012-02-01 00:00:00

pages

231-5

issue

2

eissn

0268-3369

issn

1476-5365

pii

bmt201173

journal_volume

47

pub_type

杂志文章

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure.

    abstract：:Numerous studies have reported the feasibility and safety of autologous SCT (ASCT) in patients with multiple myeloma (MM) and mild to moderate renal impairment, but there are limited data in dialysis-dependent patients. In this retrospective study, we reviewed the toxicities and efficacy outcomes of 33  MM patients wi...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/bmt.2014.226

    authors： St Bernard R,Chodirker L,Masih-Khan E,Jiang H,Franke N,Kukreti V,Tiedemann R,Trudel S,Reece D,Chen CI

    更新日期：2015-01-01 00:00:00

  • Ruxolitinib treatment for GvHD in patients with myelofibrosis.

    abstract：:Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, optimal dose and tapering schedule of ruxolitinib remain to be determined. Discontinuation of ruxolitinib in myelofibros...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2016.256

    authors： Mori Y,Ikeda K,Inomata T,Yoshimoto G,Fujii N,Ago H,Teshima T

    更新日期：2016-12-01 00:00:00

  • Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: a PRISMA-compliant meta-analysis.

    abstract：:We should consider both the treatment effects and adverse effects of autologous hematopoietic stem cell transplantation (AHSCT) on multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD). Articles exploring the effect and safety of AHSCT in the treatment of MS and NMOSD and published before Decembe...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-0810-z

    authors： Zhang P,Liu B

    更新日期：2020-10-01 00:00:00

  • Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.

    abstract：:In an effort to reduce the relapse rate after unpurged autologous bone marrow transplantation (ABMT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1), the standard conditioning regimens (cyclophosphamide/busulphan and cyclophosphamide/TBI) were intensified by adding idarubicin. Seventeen...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1701279

    authors： Jerjis S,Roovers E,Muus P,Schaap N,de Witte T

    更新日期：1998-07-01 00:00:00

  • Complete heart block in association with graft-versus-host disease.

    abstract：:An infant who received haploidentical BM for severe combined immunodeficiency (SCID) developed acute, reversible complete heart block in association with an exacerbation of GVHD. Respiratory distress and myocardial dysfunction were also seen with this and previous GVHD exacerbations. The patient had not received chemo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701038

    authors： Gilman AL,Kooy NW,Atkins DL,Ballas Z,Rumelhart S,Holida M,Lee N,Goldman F

    更新日期：1998-01-01 00:00:00

  • Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.

    abstract：:Relapse of chronic lymphocytic leukemia (CLL) after allogeneic hematopoietic cell transplantation (HCT) remains a clinical challenge. We studied in a phase II trial whether the addition of peri-transplant rituximab would reduce the relapse risk compared with historical controls (n = 157). Patients (n = 55) received fl...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-019-0660-8

    authors： Shadman M,Maloney DG,Storer B,Sandmaier BM,Chauncey TR,Smedegaard Andersen N,Niederwieser D,Shizuru J,Bruno B,Pulsipher MA,Maziarz RT,Agura ED,Hari P,Langston AA,Maris MB,McSweeney PA,Storb R,Sorror ML

    更新日期：2020-01-01 00:00:00

  • A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.

    abstract：:We studied the effects of escalating doses of recombinant human IL-1 beta in patients receiving high-dose chemotherapy and ABMT for metastatic breast cancer or malignant melanoma. Sixteen patients received IL-1 beta, 4 to 32 ng/kg/day administered subcutaneously for 7 days beginning 3 h after bone marrow infusion. Thr...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1700633

    authors： Elkordy M,Crump M,Vredenburgh JJ,Petros WP,Hussein A,Rubin P,Ross M,Gilbert C,Modlin C,Meisenberg B,Coniglio D,Rabinowitz J,Laughlin M,Kurtzberg J,Peters WP

    更新日期：1997-02-01 00:00:00

  • Admission of bone marrow transplant recipients to the intensive care unit: outcome, survival and prognostic factors.

    abstract：:The role of ICU support in BMT patients is controversial. In an era of constrained resources, the use of prognostic factors predicting outcome may be helpful in identifying patients who are most likely (or unlikely) to benefit from this intervention. We attempted to define the survival of patients admitted to ICU foll...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701158

    authors： Jackson SR,Tweeddale MG,Barnett MJ,Spinelli JJ,Sutherland HJ,Reece DE,Klingemann HG,Nantel SH,Fung HC,Toze CL,Phillips GL,Shepherd JD

    更新日期：1998-04-01 00:00:00

  • Cognitive and adaptive behavior 1 and 3 years following bone marrow transplantation.

    abstract：:Children receiving a bone marrow transplant (BMT) are at risk for neuropsychological late effects because of potentially neurotoxic chemotherapy and total body irradiation. The goal of this study was to prospectively and longitudinally assess the intellectual and adaptive functioning of children receiving a BMT. This ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700699

    authors： Kramer JH,Crittenden MR,DeSantes K,Cowan MJ

    更新日期：1997-03-01 00:00:00

  • Allogeneic transplantation of purified CD34+ cells from peripheral blood: Spanish experience of 62 cases. Spanish Group of allo-PBT.

    abstract：:This report summarizes the Spanish experience of 62 cases of allogeneic transplantation of purified CD34+ cells from peripheral blood. HLA-identical sibling donors received G-CSF. After leukapheresis, peripheral blood progenitor cells were purified using one of two methods: Ceprate (n = 38), or Isolex 300 (n = 24). Si...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Urbano-Ispizua A,Solano C,Brunet S,de la Rubia J,Odriozola J,Zuazu J,Figuera A,Caballero D,Martínez C,García J,Sanz G,Torrabadella M,Alegre A,Pérez-Oteiza J,Jurado M,Oyonarte S,Sierra J,García-Conde J,Rozman C

    更新日期：1998-06-01 00:00:00

  • Hematopoietic SCT modulates gut inflammation in experimental inflammatory bowel disease.

    abstract：:Hematopoietic SCT (HSCT) and high-dose chemotherapy are being explored as therapy for various human refractory immune-mediated conditions, including inflammatory bowel diseases (IBD). Nevertheless, the exact immunological mechanisms by which the BM cells (BMCs) or immunosuppression provide remission from these disease...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2010.6

    authors： Godoi DF,Cardoso CR,Ferraz DB,Provinciatto PR,Cunha FQ,Silva JS,Voltarelli JC

    更新日期：2010-10-01 00:00:00

  • Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.

    abstract：:Still, many physicians give 4 cycles of combination therapy to multiple myeloma patients prior to collection of stem cells for autologous bone marrow transplant. This tradition originates from older doxorubicin-containing regiments which limited the number of cycles due to cumulative cardiotoxicity. Using older regime...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-018-0170-0

    authors： Tageja N,Korde N,Kazandjian D,Panch S,Manasanch E,Bhutani M,Kwok M,Mailankody S,Yuan C,Stetler-Stevenson M,Leitman SF,Sportes C,Landgren O

    更新日期：2018-11-01 00:00:00

  • Granisetron in the prevention of irradiation-induced emesis.

    abstract：:A double-blind double-dummy, comparative study was carried out in 30 patients receiving highly emetogenic fast dose rate, single fraction total body irradiation prior to bone marrow transplantation. Patients were randomised into one of two groups, receiving either granisetron, a specific 5-HT3 antagonist or a combinat...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Prentice HG,Cunningham S,Gandhi L,Cunningham J,Collis C,Hamon MD

    更新日期：1995-03-01 00:00:00

  • Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem cell transplantation.

    abstract：:We report two cases of severe alloimmune hemolysis after hematopoietic stem cell (HSC) transplant resulting from an anti-Jk(a). The time course of hemolysis and Jk phenotypes of the donor and recipient in the cases reported suggest that the antibody was produced by donor-derived passenger lymphocytes. Retrospective an...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703074

    authors： Young PP,Goodnough LT,Westervelt P,Diersio JF

    更新日期：2001-06-01 00:00:00

  • Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.

    abstract：:The CXCR4-inhibitor plerixafor mobilizes hematopoietic stem cells amplifying the effects of granulocyte-CSF (G-CSF). Before approval plerixafor was used in a compassionate use program (CUP) for patients who failed a previous mobilization. In the German CUP 60 patients from 23 centers (median age 56.5 years (2-75)) wer...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/bmt.2010.249

    authors： Hübel K,Fresen MM,Salwender H,Basara N,Beier R,Theurich S,Christopeit M,Bogner C,Galm O,Hartwig R,Heits F,Lordick F,Rösler W,Wehler D,Zander AR,Albert MH,Dressler S,Ebinger M,Frickhofen N,Hertenstein B,Kiehl M,L

    更新日期：2011-08-01 00:00:00

  • Controversies and challenges in HLA-haplotype-matched transplants for leukaemia.

    abstract：:Many typescripts in this issue describe increasing use of HLA-haplotype-matched transplants in persons with leukaemia and report outcomes. Consequently, my goal is not to repeat these data but to focus on controversies and challenges relevant to this topic including: (1) what is the best technique for performing these...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-019-0611-4

    authors： Gale RP

    更新日期：2019-08-01 00:00:00

  • Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.

    abstract：:Thirty patients, with high-risk acute myeloid leukemia (AML, n = 20) or myelodysplastic syndrome (MDS, n = 10), were enrolled in a phase II trial entailing prophylactic post-transplant azacitidine (AZA) plus escalated doses of donor lymphocyte infusion (DLI). The median number of AZA cycles was 5 (1-12) with 10 patien...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/s41409-019-0536-y

    authors： Guillaume T,Malard F,Magro L,Labopin M,Tabrizi R,Borel C,Chevallier P,Vigouroux S,Peterlin P,Garnier A,Rubio MT,Huynh A,Milpied N,Moreau P,Gaugler B,Yakoub-Agha I,Mohty M

    更新日期：2019-11-01 00:00:00

  • CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma.

    abstract：:A potential problem of autologous transplantation in the treatment of multiple myeloma (MM) is the infusion of tumor cells. CD34+ selection has been used to purge autografts in MM and it is also possible to reduce tumour cell contamination of autografts by cytotoxic drug therapy prior to peripheral blood stem cell (PB...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/sj.bmt.1702408

    authors： Dyson PG,Horvath N,Joshua D,Barrow L,Van Holst NG,Brown R,Gibson J,To LB

    更新日期：2000-06-01 00:00:00

  • Evaluation of uroprotective efficacy of amifostine against cyclophosphamide induced hemorrhagic cystitis.

    abstract：:The role of amifostine in the prevention of cyclophosphamide-induced hemorrhagic cystitis (HC) was evaluated in the rat model. Urinary bladders from control rats that received no drugs (group I) were compared with those from rats receiving cyclophosphamide alone at a dose of 150 mg/kg (group II), and two other groups ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701598

    authors： Srivastava A,Nair SC,Srivastava VM,Balamurugan AN,Jeyaseelan L,Chandy M,Gunasekaran S

    更新日期：1999-03-01 00:00:00

  • Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.

    abstract：:Superiority of single-donor apheresis platelets (SDAP) over pooled platelet concentrates (PPC) transfusions is largely assumed, but unproven. We hypothesized that prophylactic SDAP and PPC transfusions are clinically equivalent after allogeneic hematopoietic stem cell transplants (HSCT). We studied all transfusions ad...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705751

    authors： Gurkan E,Patah PA,Saliba RM,Ramos CA,Anderson BS,Champlin R,de Lima M,Lichtiger B

    更新日期：2007-09-01 00:00:00

  • Survival time of cardiac allografts prolonged by isogeneic BMT in mice.

    abstract：:To find an approach to prolong the survival time of cardiac allografts in a BALB/c-to-C57/BL6 heterotopic heart transplant model and to try to figure out related chemokines and cytokines, isogeneic and allogeneic BM cells were obtained from pregnant C57/BL6 (♀C57/BL6 × ♂BALB/c) and regular BALB/c mice and injected to ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2011.215

    authors： Chen Z,Jiang H,Chen R,Feng S,Jin J,Bi Y,Yang H,Chen J

    更新日期：2012-08-01 00:00:00

  • Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.

    abstract：:Seventy consecutive patients with refractory or relapsed Hodgkin's disease who received high-dose chemotherapy followed by autologous stem cell rescue were analyzed to identify clinically relevant predictors of long-term event-free survival. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytara...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701325

    authors： Lancet JE,Rapoport AP,Brasacchio R,Eberly S,Raubertas RF,Linder T,Muhs A,Duerst RE,Abboud CN,Packman CH,DiPersio JF,Constine LS,Rowe JM,Liesveld JL

    更新日期：1998-08-01 00:00:00

  • Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.

    abstract：:Infectious complications were retrospectively analyzed in 129 transplants, performed in 90 patients, to identify characteristics that qualify breast cancer patients for outpatient-based PBSCT. Thirty-one cases (24%) did not develop fever. Of the remaining 98 cases, 84.7% developed fever during severe neutropenia. On u...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703246

    authors： Morabito F,Irrera G,Oliva E,Console G,Martino M,Pucci G,Messina G,Barbaro P,Palazzo S,Iacopino P

    更新日期：2001-11-01 00:00:00

  • Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen.

    abstract：:The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some r...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705712

    authors： Smith SD,Bolwell BJ,Rybicki LA,Brown S,Dean R,Kalaycio M,Sobecks R,Andresen S,Hsi ED,Pohlman B,Sweetenham JW

    更新日期：2007-08-01 00:00:00

  • Circulating stem cell autografts.

    abstract：:The role of autologous bone marrow transplantation in the treatment of malignant disease is currently being evaluated. The peripheral blood represents an alternative source of haemopoietic progenitors and the use of circulating rather than bone marrow stem cells permits autografting in patients with infiltrated bone m...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Bell AJ,Hamblin TJ,Oscier DG

    更新日期：1986-12-01 00:00:00

  • Stem cell enumeration in cord blood vs bone marrow and peripheral blood.

    abstract：:Recent reports have suggested that the total number of autologous or allogeneic hematopoietic stem cell (HSC) infused after high-dose chemotherapy might predict survival, post-transplant morbidity and rate of hematopoietic engraftment. However, HSC capable of long-term multilineage potential are still poorly defined, ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Bertolini F,Battaglia M,Lanza A,Gibelli N,Palermo B,Pavesi L,Robustelli della Cuna G

    更新日期：1998-07-01 00:00:00

  • Secondary oral cancer following hematopoietic cell transplantation.

    abstract：:The aim of this retrospective study was to determine the incidence and the clinical outcome of secondary oral cancer (SOC) and to assess potential risk factors in a large cohort of patients (n = 908), who received allogeneic hemopoietic cell transplantation (HCT) either for a malignant (n = 733) or nonmalignant hemato...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01147-z

    authors： Santarone S,Natale A,Angelini S,Papalinetti G,Vaddinelli D,Di Bartolomeo A,Di Bartolomeo P

    更新日期：2020-11-24 00:00:00

  • Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT.

    abstract：:These recommendations were prepared by the European Conference on Infections in Leukaemia following a predefined methodology. Literature searches were made to identify studies pertinent to management of CMV, HHV-6, -7 and -8 infections. For CMV, 76 studies were reviewed: 72 published and 4 presented as abstracts. Twen...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,实务指引

    doi：10.1038/bmt.2008.162

    authors： Ljungman P,de la Camara R,Cordonnier C,Einsele H,Engelhard D,Reusser P,Styczynski J,Ward K,European Conference on Infections in Leukemia.

    更新日期：2008-08-01 00:00:00

  • Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future.

    abstract：:beta-Thalassemia major and sickle cell disease (SCD) are among the most common hereditary disorders worldwide. The supportive treatment of beta-thalassemia major requires chronic, life-long RBC transfusions, which cause progressive iron overload and the potential for impaired endocrine, cardiac and hepatic function. T...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1705943

    authors： Bhatia M,Walters MC

    更新日期：2008-01-01 00:00:00

  • Absence of IL-23p19 in donor allogeneic cells reduces mortality from acute GVHD.

    abstract：:The p19 dimer of interleukin 23 (IL-23) has been reported to have a major role in the pathogenesis of many experimental and clinical autoimmune diseases and may also have a prominent role in transplantation. We reasoned that deficiency of p19 in the allogeneic donor transplant might reduce the inflammation caused by a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2009.215

    authors： Thompson JS,Chu Y,Glass JF,Brown SA

    更新日期：2010-04-01 00:00:00